XASE · Healthcare · Medical Devices
Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | Q1 2026 | -0.30 | -0.25 | +16.67% | $76,000 | ✅ Beat | +0.26% | -3.09% | — |
| 2026-03-16 | Q4 2025 | -0.35 | -0.51 | -45.71% | $43,000 | ❌ Miss | -0.38% | -18.77% | -16.09% |
| 2025-11-10 |
| Q3 2025 |
| -0.32 |
| -0.35 |
| -9.38% |
| $209,000 |
| ❌ Miss |
| — |
| — |
| — |
| 2025-08-13 | Q2 2025 | -0.29 | -0.30 | -3.45% | $290,000 | mixed | -1.76% | -11.29% | -8.66% |
| 2025-03-26 | Q4 2024 | -0.26 | -0.60 | -130.77% | $234,000 | ❌ Miss | +1.32% | -9.69% | +5.29% |
| 2024-11-12 | Q3 2024 | -0.21 | -0.21 | +0.00% | $369,000 | ➖ Inline | -6.94% | -36.46% | -67.48% |
| 2024-08-12 | Q2 2024 | -0.21 | -0.17 | +19.05% | $526,000 | ✅ Beat | +5.71% | +17.12% | +29.45% |
| 2024-05-15 | Q1 2024 | -0.20 | -0.20 | +0.00% | $325,000 | ➖ Inline | -2.55% | -5.10% | -31.85% |
Showing last 8 quarters.